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Summary 
Background: Unfavorable lipid profile presents one of
most important risk factor for cardiovascular disease in
renal pathology. Myeloperoxidase (MPO) as enzyme
which oxidizes lipoproteins and paraoxonase1 (PON1) as
anti-oxidative enzyme have been involved in pathogenesis
of cardiovascular disease. In the present study we sought
to assess oxidative stress status, lipoprotein subclasses
distribution as well as functionality of high density
lipoprotein (HDL) trough MPO/PON1 ratio in children
with chronic kidney disease (CKD) and children after
renal transplantation. 
Methods: PON1 activity and oxidative stress parameters
were measured spectrophotometrically, while MPO con-
centration was determined using immunoassay. Separation
of lipoprotein subclasses was performed by vertical gradi-
ent gel electrophoresis in 19 children with different stage
of CKD and 19 post-transplantation patients (PT). 
Results: CKD patients had increased MPO/PON1 ratio and
higher prevalence of smaller HDL subclasses when com-
pared to PT subjects.  Also, there was a significant positive
correlation between MPO level and MPO/PON1 ratio with
relative proportion of smaller HDL subclasses. 
Conclusions: Children with CKD have impaired HDL distri-
bution that is improved after kidney transplantation. Since
that measurement of HDL distribution and functionality are
Kratak sadr`aj
Uvod: Displipidemija predstavlja jedan od osnovnih faktora
rizika za razvoj kardiovaskularnih bolesti kod pacijenata sa
hroni~nim bubre`nim bolestima (CKD). Mijeloperoksidaza
(MPO) je enzim koji dovodi do oksidativne modifikacije
lipoproteinskih ~estica, dok sa druge strane, paraoksonaza
1 (PON 1) predstavlja antioksidativni enzim koji spre~ava
ove procese. Cilj ove studije bio je ispitivanje oksidativno-
stres nog statusa i raspodele lipoproteinskih ~estica kod dece
sa razli~itim stadijumima CKD i nakon transplantacije bu -
brega. Tako|e, u ovoj studiji je ispitivan odnos MPO/PON1
i njegova veza sa promenama distribucije HDL. 
Metode: U studiji je u~estvovalo 19 dece u razli~itim stadi-
jumima CKD i 19 dece nakon transplantacije bubrega
(PT). Parametri oksidativno-stresnog statusa i aktivnost en -
zima PON 1 odre|eni su spektrofotometrijskim metodama,
dok je koncentracija MPO odre|ena imunoesejem. Raz -
dva janje lipoproteinskih subfrakcija vr{eno je metodom ver-
tikalne gradijent gel elektoforeze. 
Rezultati: U CKD grupi su dobijene statisti~ki zna~ajno vi{e
vrednosti odnosa MPO/PON1, kao i ve}i procenat malih
HDL ~estica u pore|enju sa PT grupom. Tako|e, uo~ena je
statisti~ki zna~ajna pozitivna korelacija izme|u MPO/PON1
odnosa i relativnog udela malih, HDL ~estica kod ovih paci-
jenata. 
Non-standard abbreviations: AOPP, Advanced oxidation
protein products; MPO, Myeloperoxidase; PON 1, Para -
oxonase 1; SH groups, Total sulphydryl groups; TBARS,
The thiobarbituric acid-reacting substances.
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Introduction
Chronic kidney disease (CKD) is associated with
profound changes in lipid homeostasis and therefore,
dyslipidemia is one of leading co-morbidities in these
patients (1). Kidney transplantation is a treatment of
choice for CKD and recent data suggest that trans-
plantation can resolve deleterious effects of kidney
impairment to the lipid profile (2). However, there is
a sample of evidence suggesting persistent dyslipi-
demia even after transplantation, mostly due to pro-
longed use of immunosuppressive medication (3, 4).
It is important to mention that most of analyses were
based on assessment of routine lipid profile markers,
such as concentration of low-density (LDL) and high-
density (HDL) cholesterol and triglycerides (TG),
while less is known about distribution of lipoprotein
subclasses in CKD patients and after transplantation,
especially in younger population. Yet, children and
adolescents are very vulnerable population having in
mind deleterious effects of lipid disorders in early life
on future cardiovascular health in adulthood (5).
Therefore, advanced lipid profile analysis could be
beneficial for better understanding of changes of lipid
homeostasis in CKD and following renal transplanta-
tion in younger age.
In addition, contemporary research emphasize
quality and resultant functionality of lipoprotein parti-
cles as far more important determinants of dyslipi-
demia then routinely assessed concentrations of lipid
status markers. Functionality of HDL subclasses is of
particular interest, because of their complex composi-
tion and their propensity toward profound changes
due to alterations of other lipid, inflammatory and
redox status parameters (6). However, assessment of
HDL functional properties is difficult to achieve and
therefore several surrogate markers are proposed.
Recently, a ratio between myeloperoxidase (MPO)
and paraoxonase 1 (PON1) was suggested as a com-
petent indicator of HDL functionality (7). Giving that
both MPO as a pro-oxidative and pro-inflammatory
agent and PON1 as a powerful component of anti-
oxidative defense system, are already recognized as
important mediators of CKD-associated metabolic
disorders (8, 9), it would be important to analyze their
relationship in children with CKD and after renal
transplantation, as well as their association with HDL
subclasses distribution.
The aim of this study was to explore distribution
of LDL and HDL subclasses in children and adoles-
cents with CKD and after renal transplantation. Also,
we aimed to explore levels of adipocytokines, markers
of oxidative stress and anti-oxidative defense in study
groups, as well as to explore their associations with
HDL profile. Finally, we sought for associations
between MPO, PON1 and HDL subclasses in youths
with CKD and after transplantation.
Materials and Methods
Patients
For this study, we recruited 19 children and ado-
lescent (aged 3–21) in various stages of CKD.
Hemodialysis treatment was applied in 10 patients,
while 9 patients were in pre-dialysis stage. Other
study group was formed by 19 age and sex-matched
post-transplantation (PT) patients. Post-transplanta-
tion interval was no shorter than 1 year (median: 3;
interquartile range: 1–5.3 years). 79% of PT patients
were previously treated by hemodialysis. All patients
were selected from Nephrology Department
University Children's Hospital in Belgrade. Exclusion
criteria were primary cardiovascular disease, diabetes
mellitus, acute infection or use of any hypolipemic
medication.
Prior to the enrolment, informed consent was
obtained from all participants. In case of minors, par-
ents or tutors gave consent for involvement in the
research. Entire study was planned and executed
according to the ethical guidelines of the Helsinki
Declaration. Local ethical committees of University
Children's Hospital and Faculty of Pharmacy
approved the study protocol.
At the study entry basic demographic and
anthropometric data were collected. Body-mass index
(BMI) was derived from weight and height, while
waist and hip circumferences were used to calculate
waist-to-hip ratio (WHR)
Biochemical analyses
Blood samples were taken after a 12-hour fast-
ing period. Plasma and serum were separated by
immediate centrifugation at 1500 × g for 10 minutes
at 4 °C and then stored at –80 °C till analyses.
Concentrations of total cholesterol (TC) and
triglycerides (TG) were measured by routine enzymat-
ic methods using an ILab 300+ analyzer (Instru -
mentation Laboratory, Milan, Italy) and Randox
not routinely available, MPO/PON1 ratio may be useful
marker that could provide necessary information.
Keywords: chronic kidney disease, HDL particles,
myeloperoxidase
Zaklju~ak: Rezultati ove studije pokazuju da transplantacija
kod dece sa hroni~nim bolestima bubrega dovodi do
pomeranja raspodele HDL subfrakcija ka ~esticama sa bolje
o~uvanim funkcionalnim svojstvima. Odnos MPO/PON1
mo`e biti koristan marker funkcionalnosti HDL.
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Laboratories (Armdore, UK) reagents. HDL-choles-
terol (HDL-C) level was assessed by precipitation-
method with phosphotungstic acid in the presence of
magnesium ions. LDL-cholesterol (LDL-C) was deter-
mined by Friedwald’s formula. Concentrations of
apolipoprotein AI (apoAI) and apolipoprotein B-100
(apoB) were measured by immunoturbidimetric
method using the ILab 600 analyser and Dialab
(Vienna, Austria) reagents.
Oxidative stress, anti-oxidative defence and
adipocytokine concentrations
The thiobarbituric acid-reacting (TBARS) con-
centration was measured using its molar absorption
coefficient of 1.56 × 105 M-1 at 535 nm, previously
described by Girotti (10). The intra-assay and inter-
assay coefficients of variance were 4.8 % and 7.2%
respectively. Concentration of advanced oxidation
protein products (AOPP) were measured according to
Witko-Sarsat (11), employing spectrophotometry at
340 nm. AOPP concentrations were expressed as
chloramine-T equivalents. The rate of nitroblue tetra-
zolium (NBT) reduction was used to measure the rate
of O2.- generation, as described by Auclair and Voisin
(12) (the intra-assay and inter-assay coefficients of
variance were 5.6% and 9.5%, respectively). MPO
concentration was assayed by using the two-site sand-
wich Elisa assay (Immundiagnostik AG, Bensheim,
Germany). 
As a markers of antioxidative defence we meas-
ured the concentration of total sulphydryl (SH) groups
in plasma and PON 1 activity. SH groups concentra-
tion in plasma was determined using 0.2 mmol/L
5,5’-dithiobis (2-nitrobenzoic acid) (DTNB) reported
by Ellmann (13). DTNB reacts with aliphatic thiols (at
pH 9.0) producing 1 mole of p-nitrophenol per mole
of thiol. p-Nitrophenol was measured by spectropho-
tometry at 412 nm. PON1 paraoxon (POase activity)
hydrolysis rates was measured spectrophotometrically
in serum using a continuous reading spectropho-
tometer (Pharmacia LKB, Cambrige, UK) according
to Richter and Furlong (14). The concentrations of
paraoxon was 1.2 mmol/L. Paraoxon was purchased
from Chem Service (West Chester, PA, USA). 
Total plasma adiponectin concentration was
measured in duplicate and assayed by an enzyme-
linked immunosorbent assay (ELISA) method (Hu -
man Adiponectin/Acrp30 Immunoassay, Quan tik ine,
R&D systems, Minneapolis, Minnesota, USA). The
con centration of leptin in plasma was determined
using a Leptin (sandwich) ELISA Kit (DRG Instru -
ments, Marburg, Germany).
MPO/PON1 ratio was determined by subtract-
ing MPO mass concentration by PON1 activity as pre-
viously suggested (7).
Determination of LDL and HDL subclasses
Separation of lipoprotein subclasses was per-
formed by using the method of vertical 3–31% poly-
acrylamide gradient gel electrophoresis (15). After
staining the gels, further analysis was accomplished
using Image Scanner (Amersham Pharmacia Biotech,
Vienna, Austria) with Image Quant software (version
5.2;1999; Molecular Dynamics). Calibration curve
was created based on electrophoretic mobility of
Pharmacia High Molecular Weight protein standards
and carboxylated polystyrene microsphere beads.
Particle diameters corresponding to detected
absorbance peaks were determined and each peak
was classified into adequate LDL or HDL subclasses
region. Assessed diameters of major peaks in LDL
and HDL regions of each sample were designated as
dominant LDL and HDL particle sizes. Relative pro-
portions of individual subclasses were estimated by
determination of areas under the peaks in correspon-
ding LDL and HDL subclasses regions. Relative pro-
portion of small, dense LDL (sdLDL) particles was
determined as the fraction of the area under the peak
at or below 25.5 nm in LDL region of the scan.
Correspondingly, relative proportion of small HDL
subclasses (HDL 3) was determined as the percent-
age of the area under the peak at or below 8.8 nm in
HDL region of individual scan.
Statistical analysis
Normally distributed variables were expressed as
means ± standard deviations (SD) and compared by
the Student’s t-test. TG concentration had log-normal
distribution, so it was expressed or as geometrical
means and the 95% confidence intervals. Asymme -
trically distributed values were presented as medians
and interquartile ranges and compared by the Mann-
Whitney U-test. Categorical variables were shown as
absolute frequencies and analysed using the Chi-
square test for contingency tables. 
Spearman's correlation analysis was employed
to examine correlations between characteristics of
HDL particles and other examined parameters.
Spearman’s rho value was used for screening the
independent variables. We used binary logistic regres-
sion (multiple logistic regression, enter model) to seek
possible independent association between increased
prevalence of smaller HDL subclasses and investigat-
ed parameters which showed significant association
with small HDL subclasses in correlation analysis. An
increased prevalence of smaller HDL particles in an
individual sample was considered if the relative pro-
portion of HDL 3 was equal or above the upper quar-
tile and was coded 1, while the smaller prevalence in
an individual was coded 0. For each odds ratio (OR)
we estimated two-tailed probability values and the
95% confidence interval (95% CI). All statistical anal-
yses were performed using PASW Statistics version
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18.0 and MedCalc Software version 11.4.
Differences with P<0.05 were considered to be sta-
tistically significant.
Results
Basic clinical and laboratory data are presented
in Table I. As it can be seen, both groups are age and
gender matched, but CKD patients had lower BMI,
although statistical significance did not reached. In
addition, CKD patients had lower WHR. Other routine
biochemical markers did not differ between the
patients in two examined groups, but it should be
noticed that concentrations of TG were markedly
above the recommended values in both cohorts.
Next we analyzed advanced lipid profile and lev-
els of adipocytokines and oxidative stress markers in
CKD and PT patients (Table II). We found no differ-
ences in LDL particle size, as well as in relative pro-
portion of sdLDL in both groups. In contrast, differ-
ences in HDL particles profiles between CKD and PT
patients were significant. CKD patients had smaller
mean HDL particle size and relative proportion of
larger HDL 2b particles, alongside with increased
prevalence of smaller HDL 3a, 3b and 3c subclasses.
Regarding levels of adipocytokines, concentrations of
leptin were comparable in the examined groups,
while concentrations of adiponectin were significantly
higher in CKD patients. Finally, concentrations of
markers of oxidative stress and antioxidative defense
were similar in both groups with an exception for SH
groups and MPO, although with borderline signifi-
cance. More importantly, MPO/PON1 ratio was sig-
nificantly higher in CKD patients when compared to
PT subjects (Table II).
Correlation analysis revealed significant associa-
tions of determined HDL particle characteristics with
other examined markers (Table III). Expectedly, we
found that HDL particle size was negatively correlated
with TG and positively with HDL-C levels. Also, large
HDL 2b subclasses were in positive and smaller HDL
3a and 3b particles in negative correlation with HDL-
C concentration. In addition, proportion of HDL 3a
was in positive association with TG level, but in nega-
tive with WHR. Further analysis has shown that of all
markers of redox status, only activity of SOD negative-
ly correlated with HDL size. Also, we observed posi-
tive association between adiponectin level and pro-
portion of HDL 3b. Lastly, we found significant
positive correlation of MPO level and MPO/PON1
ratio with relative proportion of smaller HDL 3a and
3b subclasses (Table III).
In order to further elucidate the observed rela-
tionships, we performed binary logistic regression
analysis with an aim to explore independent determi-
nants of higher presence of smaller HDL particles
(Table IV). Binary logistic regression analysis included
all variables that were associated with smaller HDL
subclasses in previous consideration. As a result, only
MPO/PON1 ratio was revealed as an independent
predictor of higher presence of smaller HDL particles
in our examinees (Table IV).
Table I Basic demographic and laboratoryparameters in two study groups.
Data are expressed as mean ± SD; 
*Values are expressed as geometric means and 95th confidence intervals 





Gender (m/f) 8/11 12/7 0.194
Age (years) 14.05 ± 4.87 15.11 ± 3.26 0.439
BMI  (kg/m2) 17.86 ± 3.67 20.01 ± 3.53 0.084
WHR 0.85 ± 0.07 0.91 ± 0.08 0.046
Total protein (g/L) 65.78 ± 6.25 68.32 ± 5.76 0.207
TC  (mmol/L) 4.58 ± 0.96 4.90 ± 0.94 0.319
LDL-C (mmol/L) 2.51± 0.83 2.76 ± 0.71 0.328
HDL-C (mmol/L) 1.20 ± 0.40 1.37 ± 0.54 0.284
TG* (mmol/L) 1.73 (0.45–2.56) 1.40 (0.8-2.6) 0.262
ApoAI (g/L) 1.62 ± 0.46 1.66 ± 0.45 0.815
ApoB (g/L) 0.98 ± 0.22 0.99 ± 0.25 0.903
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Table II Advanced lipid status profile, adipocytokines and oxidative stress parameters in analyzed groups.




LDL particle size (nm) 25.96±1.96 26.22±1.30 0.636
sdLDL (%) 50.62±5.41 49.42±4.10 0.448
HDL particle size (nm) 9.48±1.04 10.59±0.80 0.001
HDL 2b (%) 39.28±5.43 48.64±4.85 <0.001
HDL 2a (%) 21.27±2.13 22.58±2.28 0.077
HDL 3a (%) 16.77±2.60 14.00±2.19 <0.001
HDL 3b (%) 10.14±2.13 7.52±1.53 <0.001
HDL 3c (%) 12.56±6.52 7.17±1.49 0.002
Leptin (pg/mL)* 4.40 (2.00–11.90) 5.10 (2.10–27.90) 0.644
Adiponectin (g/mL) 26.92±14.13 18.01±11.31 0.048
SH-groups (g/L) 0.46±0.10 0.52±0.06 0.026
O2- (mmol/min/L) 203.43±65.16 187.23±51.39 0.401
AOPP (mmol/L) * 25.13(18.32–31.39)
20.26
(15.83–27.62) 0.216
SOD (kU/L) 105.48± 38.11 93.85±12.91 0.221




TBARS  (mmol/L) 1.72±0.36 1.58±0.41 0.271
MPO (mg/L)* 138.05 (54.25–192.26) 61.69 (34.58–135.74) 0.086
MPO/PON1 ratio* 0.57 (0.21–0.76) 0.15 (0.07–0.60) 0.032
Data are expressed as mean ± SD and compared by Student-t test
*Values are expressed as medians and interquartile ranges and compared by Mann-Whitney U-test
Results are presented as Pearson’s correlation coefficients.
#Results are presented as Spearman’s rho coefficients due to asymmetric distribution of analyzed data; *P <0.05; ** P <0.01
Parameter HDL particle size (nm) HDL 2b (%) HDL 2a (%) HDL 3a (%) HDL 3b (%) HDL 3c (%)
Age (years) 0.153 0.107 -0.014 0.001 -0.021 -0.118
BMI (kg/m2) 0.120 0.151 0.293 -0.201 -0.112 -0.160
WHR 0.254 0.226 0.284 -0.351* -0.216 -0.149
TG (mmol/L) -0.277* -0.168 0.246 0.320* 0.252 -0.146
HDL (mmol/L) 0.323* 0.359* -0.270 -0.396* -0.389* 0.005
LDL (mmol/L) 0.065 -0.055 0.192 0.044 0.112 -0.072
ApoAI (g/L) 0.253 0.216 -0.223 -0.227 -0.228 0.016
ApoB (g/L) 0.024 -0.087 0.156 0.126 0.243 -0.109
LDL particle size (nm) 0.111 0.026 0.407* -0.077 0.042 -0.180
sdLDL (%) 0.061 -0.040 -0.250 0.002 0.080 0.112
POase (U/L) -0.001 -0.019 0.094 -0.187 -0.274 0.190
SH-groups (g/L) 0.036 0.037 0.146 -0.165 -0.235 0.069
SOD (kU/L) -0.354* -0.102 0.089 0.144 -0.017 0.031
O2- (mmol/min/L) -0.212 -0.194 -0.050 0.116 0.271 0.108
AOPP (mmol/L) -0.242 -0.211 -0.098 0.236 0.303 0.066
TBARS  (mmol/L) -0.159 -0.063 0.245 0.245 0.261 -0.251
Leptin (pg/mL)# -0.012 0.093 0.087 -0.140 -0.210 -0.114
Adiponectin (g/mL) 0.004 -0.206 -0.201 0.257 0.390** 0.058
MPO (mg/L)# -0.251 -0.248 0.000 0.345* 0.289 0.108
MPO/PON1 ratio# -0.241 -0.196 -0.100 0.364* 0.355* 0.137
Discussion
Dyslipidemia is one of the major health con-
cerns in patients with CKD. Lipid disorders are pivotal
risk factors for development of cardiovascular compli-
cations which are the main causes of death in these
patients (1). Prolonged dyslipidemia in youths with
CKD could have especially detrimental effect in later
adult life, therefore resolving dyslipidemia in this cat-
egory of patients is of particular interest.
In this paper, we compared lipid profile in chil-
dren and adolescents with CKD and after renal trans-
plantation aiming, to determine whether transplanta-
tion leads to the improvement of lipid disorders.
Regarding routine lipid markers, we found no differ-
ences between CKD and PT groups (Table I).
Furthermore, PT patient had higher BMI and WHR,
although the groups were sex and age matched.
However, interpretation of anthropometric markers of
adiposity in individuals with kidney impairment is dif-
ficult, due to malnutrition, inflammation and reduced
muscle mass which often accompany CKD (16).
Therefore, observed significantly lower WHR in CKD
patients arises more likely from malnutrition-inflam-
mation-cachexia syndrome, than it is a reflection of
improved lipid profile. 
Thompson et al. (2) suggested an enhancement
of lipid status following renal transplantation. Our
preliminary results (Table I) did not confirm such find-
ings. However, more precise analysis of lipoprotein
size and subclasses yielded results that are in agree-
ment with the previous research (2). Although we did
not find differences in LDL size and prevalence of
sdLDL particles, we did observe significant changes in
HDL size and particle distribution (Table II). Namely,
our results clearly demonstrated enlarged HDL parti-
cle size and increased presence of larger HDL parti-
cles in PT patients. HDL particles are generally con-
sidered atheroprotective, due to their involvement in
reverse cholesterol transport and their battery of anti-
inflammatory, anti-oxidative and anti-thrombotic
compounds (17). However, it is nowadays widely
accepted that different HDL subclasses possess vari-
ous protective abilities in term that in healthy individ-
uals smaller HDL particles are the most efficient pro-
tective agents. On the other hand, dyslipidemia,
oxidative stress and inflammation cause profound
changes in HDL structure and function. Previous
researches demonstrated that smaller HDL subclass-
es are particularly prone to these effects, so that they
quickly lose their atheroprotective properties and may
even become proatherogenic (7, 17). Having in mind
that inflammation, dyslipidemia and oxidative stress
are hallmarks of CKD, it is reasonable to presume
that increased smaller HDL particles in this group
demonstrate deficiency of atheroprotective mecha-
nisms and may lead to accelerate atherosclerosis. In
contrast, significantly reduced presence of smaller
HDL particles in PT patients provides confirmation of
previous findings (18) that renal transplantation could
lead to improvement of dyslipidemia. It is important
to mention that in previous research (18), we demon-
strated less favorable HDL distribution in pediatric
renal transplant recipients when compared to healthy
children. Taken all together, our results imply that lipid
disorders of CKD are ameliorated following transplan-
tation, but dyslipidemia-associated cardiovascular risk
should not be neglected even in post-transplantation
period, particularly because of prolonged use of
immuno suppressive medication. 
Even it is good known that adiponectin has car-
dio protective and anti-inflammatory effects, the role
of this adipocytokine in patients with CKD are still
unclear (19). Results of previous studies have con-
firmed a positive association between adiponectin
concentration and progression of CKD (19). The
main reasons for high adiponectin concentrations in
uremic patients are reduced adiponectin clearance by
the impaired kidneys and changes in adiponectin
binding for their receptors (20). In CKD patients,
higher adiponectin concentrations which are usually
more than three times higher compared with healthy
individuals are associated with poor outcomes and
increased mortality (21). Result of our study con-
firmed previous founding (19, 22) that the high levels
of adiponectin decline after renal transplantation
(Table II). Also, we found significant positive correla-
tion between adiponectin concentration and presence
of smaller HDL 3b particles (Table III), so we could
speculate that even adiponectin is presumed to pos-
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Table IV Multiple logistic regression analysis for predictors of increased proportion of HDL 3 sublasses.
Predictors OR CI (OR) P
MPO/PON1 ratio 5.033 1.179–21.486 0.029
TG (mmol/L) 0.463 0.091–2.360 0.354
WHR 0.000 0.000–54.891 0.120
Adiponectin (g/mL) 0.971 0.864–1.091 0.620
HDL (mmol/L) 0.457 0.091–2.360 0.690
Variables included in the model were selected according previously detected associations with HDL 3 subclasses in univariate cor-
relation analysis. Increased proportion of HDL 3 subclasses was considered if relative proportions of HDL 3 particles were equal
or above the upper quartile.
sess antiatherogenic properties in the uncommon
uremic milieu, higher adiponectin levels are associat-
ed with increased risk for cardiovascular disease
development. For sure, this complex role of adipo -
nectin in CKD, needed to be investigated on deeper
levels, especially in pediatric patients. 
A number of studies suggest that CKD is a condi-
tion allowing a higher possibility of oxidative stress
development (23). Impaired mitochondrial respiratory
system could be considered both, as the consequence
and the cause of increased production of reactive oxy-
gen species (ROS), leading to damage to different
intra- and extracellular structures. Our previous results
showed that renal disease patients were in a state of
stronger oxidative stress compared with healthy chil-
dren (24). In this study, we failed to find some statisti-
cally significant differences in parameters of oxidative
stress status between CKD patients and PT patients
(Table II). This result is in agreement with previous re -
searches, were general conclusion could be that even
kidney transplantation is the ideal treatment for
patients with end-stage kidney disease, the intensive
oxidative stress is still one of the biggest problem for
those patients and probably the major molecular medi-
ator of adverse outcomes throughout the course of
transplantation (25). Also, due to the fact that oxi dative
stress affect both short-term and long-term survival of
PT patients different prophylactic approaches should
be employed in order to reduce oxidative stress.
But, even results of our study generally didn't
showed some significant changes in oxidative status
parameters, very important finding of this study was
markedly higher concentration of MPO in CKD
patients then in PT subjects (Table II), although with
borderline significance. It has been previously demon-
strated that MPO, as a link between oxidative stress
and inflammation, was elevated in CKD (25). Our
results imply differences in level of MPO in CKD and
after dialysis, which should be tested in larger samples.
Also, it is very important to notice that, PON1 activity
was higher (borderline significance) in PT patients
compared with CKD (Table II). PON1 (aryldialkylphos-
phatase, EC 3.1.8.1) is a HDL-associated esterase that
metabolizes oxidized lipids and has a high antioxida-
tive potential (26). Low serum PON1 activity consti-
tutes a risk factor for cardiovascular disease which are
the leading cause of mortality in patients with CKD
(27). In addition, we found significant differences in
MPO/PON1 ratio which could suggest some specific
perturbations in oxidative stress status in PT patients
which maybe could not been seen as general improve-
ment of oxidative status, but indicate the existence of
some progress after the transplantation (Table II).
Based on these findings, domination of pro-oxidants
and possibilities of oxidative damage was more promi-
nent in CKD than in PT patients, even though we did
not observe such differences by examining other
markers of redox status. More importantly, altered
MPO/PON1 levels implicate disturbances in HDL
structure and function, which is a complementary
result with the observed changes of HDL particle dis-
tribution in CKD patients. Namely, it has been shown
that MPO, PON1 and apoAI are critically important for
adequate HDL function (28). Therefore, increased
MPO/PON1 level founded in CKD patients complete-
ly fit to our finding of more prevalent dysfunctional
smaller HDL particles in this group. 
To further explore this hypothesis, we performed
correlation analysis (Table III). Indeed, increased
MPO/PON1 ratio was associated with higher relative
proportions of smaller HDL 3a and 3b subclasses,
which confirms previous results. Furthermore, logistic
regression analysis revealed MPO/PON1 ratio as a
significant and independent predictor of increased
pre sence of smaller HDL particles (Table IV). Pre -
viously, Haraguchi et al. (7) proposed MPO/PON1
ratio as a useful index of impaired HDL functionality.
In this study, we confirmed such findings. Although we
did not explore HDL functional properties directly, we
demonstrated that increased prevalence of smaller
HDL particles, which are in CKD and PT individuals
most likely dysfunctional, goes alongside with in -
creased MPO/PON1 level. Since determinations of
HDL distribution as well as HDL functional properties
demand complex procedures which are not routinely
available, MPO/PON1 ratio might be easy reachable
and useful alternative that could provide necessary
information.
There are several drawbacks. First, in this study
we compared a group of children and adolescents
with CKD with a group of renal transplant recipients.
Even though the groups were age and gender
matched, it would be more effective that comparison
was done between the same subjects prior and after
transplantation. Second, the study is performed with
relatively small sample size. It is possible that some
additional associations should be detected with a
larger sample.
In conclusion, our results demonstrated that chil-
dren and adolescents with CKD have impaired HDL
distribution that is improved after kidney transplanta-
tion. MPO/PON1 ratio is strongly and independently
associated with increased prevalence of smaller HDL
particles, making MPO/PON1 ratio a useful marker of
HDL functionality. Our findings emphasize the impor-
tance of advanced lipid testing in young patients with
CKD, but also in kidney transplant recipients, which
should be further explored by larger studies.
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